Zelluna Immunotherapy AS is a pharmaceutical company that specializes in the development of cell therapies for the treatment of cancer. The company focuses on solid tumors, which represent a significant challenge in cancer treatment. Through its unique and proprietary TCR-NK cell therapy platform, Zelluna works to develop innovative solutions for patients with various forms of cancer.
TCR-NK therapies have the potential to address a broad spectrum of solid cancers, and the company targets high-value markets with unmet medical needs. Zelluna Immunotherapy AS has already shown promising results in the treatment of late-stage cancer, and has several approved treatments for liquid forms of cancer. The company's work contributes to progress in cancer research and treatment, with the aim of improving the quality of life for cancer patients.
